Prefibrotic Chronic Idiopathic Myelofibrosis – A Diagnostic Enigma?

To analyze precursor lesions of chronic idiopathic myelofibrosis (CIMF) 21 patients were recruited who developed manifest myelofibrosis after about 70 months, preceded by a prefibrotic stage but without interference by cytoreductive therapy. Prodromal bone marrow lesions included a prominent granulocytic and megakaryocytic proliferation with megakaryocytes showing conspicuous abnormalities associated with a borderline to slight anemia, thrombocytosis, and minimal splenomegaly. Comparison of this cohort with 211 additional patients at this precursor stage revealed no differences concerning clinical findings and bone marrow histopathology. Relative incidence of prefibrotic CIMF was 24% and median survival 143 months, thus contrasting overt CIMF (82 months). In CIMF progressive myelofibrosis occurred in more than 50% of patients according to the last biopsy specimen; however, this figure increased according to relevant clinical data in the follow-up period.

[1]  S. Sisti,et al.  Primary myelofibrosis: A detailed statistical analysis of the clinicopathological variables influencing survival , 1994, Annals of Hematology.

[2]  V. Diehl,et al.  Dynamics of Fibrosis in Chronic Idiopathic (Primary) Myelofibrosis During Therapy: A follow-up Study on 309 Patients , 2003, Leukemia & lymphoma.

[3]  J. Thiele,et al.  Diagnostic differentiation of essential thrombocythaemia from thrombocythaemias associated with chronic idiopathic myelofibrosis by discriminate analysis of bone marrow features--a clinicopathological study on 272 patients. , 2003, Histology and histopathology.

[4]  H. Kreipe,et al.  Evolution of myelofibrosis in chronic idiopathic myelofibrosis as evidenced in sequential bone marrow biopsy specimens. , 2003, American journal of clinical pathology.

[5]  E. Montserrat,et al.  Myelofibrosis with myeloid metaplasia following essential thrombocythaemia: actuarial probability, presenting characteristics and evolution in a series of 195 patients , 2002, British journal of haematology.

[6]  A. Tefferi Myelofibrosis with myeloid metaplasia. , 2000, The New England journal of medicine.

[7]  H M Kvasnicka,et al.  Relevance of bone marrow features in the differential diagnosis between essential thrombocythemia and early stage idiopathic myelofibrosis. , 2000, Haematologica.

[8]  G. Barosi,et al.  The Italian Consensus Conference on Diagnostic Criteria for Myelofibrosis with Myeloid Metaplasia , 1999, British journal of haematology.

[9]  A. Georgii,et al.  2 The histopathology of chronic myeloproliferative diseases , 1998 .

[10]  E. Montserrat,et al.  Myelofibrosis with myeloid metaplasia in young indidviduals: disease characteristics, prognostic factors and identification of risk groups , 1998, British journal of haematology.

[11]  A. Georgii,et al.  The histopathology of chronic myeloproliferative diseases. , 1998, Bailliere's clinical haematology.

[12]  J. Laszlo,et al.  Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. , 1997, Seminars in hematology.

[13]  P. Morel,et al.  Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. , 1996, Blood.